The Integrative Cancer Genomics Shared Resource operates a continually updated facility to provide state-of- the-art instrumentation and protocol support to Duke Cancer Institute (DCI) researchers. The Shared Resource was created by the recent merger of two existing units at Duke: the Microarray Core Facility and the Genome Sequencing and Analysis Core Facility. Each of these predecessors has a track record more than a decade long of providing constantly updated, state-of-the-art genomic services to DCI members. Until recently, however, only the Microarray Core Facility had a partnership with the DCI and was supported by it. The new Integrative Cancer Genomics Shared Resource brings all of the genomic technologies on campus under a single organization and enables comprehensive consultation, seamless management of complex projects that span multiple services, enhanced operational flexibility, and economies of scale for support services such as IT and accounting. DCI members receive scheduling priority for Shared Resource services including SNP discovery, mapping chromatin modifications, measuring mRNA levels at several scales (single genes, cancer panels, entire transcriptome), sequencing exomes, identifying DNA methylation, and mapping transcription factor binding sites. The Shared Resource assists investigators with data quality control, versioning, statistical analysis, and dissemination for all of these services. The staff includes a Director who runs his own research lab, three full-time PhD level staff members, and seven highly experienced technicians. The Resource operates primarily on a cost-recovery basis, with institutional support for a portion of the operating costs and instrument purchases. Support from the DCI and Cancer Center Support Grant allows the Resource to provide consultations and assistance with grant and manuscript preparation to DCI members free of charge. User fees for other activities follow School of Medicine guidelines. DCI members account for approximately 39% of microarray service users and 14% of DNA sequencing service users of the Integrative Cancer Genomics Shared Resource. Use of the Resource contributed to 444 DCI publications during the funding period. The immediate goal of the Resource is to complete the merger of the predecessor cores. Its long-range objectives are (1) to continue offering start-to-finish, customized support to cancer researchers seeking genomic analyses, and (2) to continually update its instrumentation and range of services to keep pace with technological advances and to meet the needs of DCI members.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :

Showing the most recent 10 out of 513 publications